Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
5 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Eton Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
7
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Eton Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
7 publishedEton Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 23, 2025 | 12,419,831 | Hydrocortisone oral liquid formulations | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| Nov 5, 2024 | 12,133,914 | Hydrocortisone oral liquid formulations | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| Feb 20, 2024 | 11,904,046 | Hydrocortisone oral liquid formulations | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| Mar 8, 2022 | 11,266,611 | More potent and less toxic formulations of epinephrine and methods of medical use | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| Dec 26, 2017 | 9,849,133 | Pharmaceutical formulations of xanthine or xanthine derivatives, and their use | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Feb 13, 2025 | 2025/0049704 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | Pharmaceuticals | Eton Pharmaceuticals, Inc. · patent 12,419,831 granted from it |
| Jul 4, 2024 | 2024/0216270 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | Pharmaceuticals | Eton Pharmaceuticals, Inc. · patent 12,133,914 granted from it |
| Jun 6, 2024 | 2024/0180820 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| May 19, 2022 | 2022/0151956 | MORE POTENT AND LESS TOXIC FORMULATIONS OF EPINEPHRINE AND METHODS OF MEDICAL USE | Pharmaceuticals | Eton Pharmaceuticals, Inc. · patent 12,290,493 granted from it |
| Dec 26, 2019 | 2019/0388498 | READY-TO-USE OXYTOCIN FORMULATION AND USES THEREOF | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
| May 9, 2019 | 2019/0134163 | ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF | Pharmaceuticals | Eton Pharmaceuticals, Inc. · patent 11,338,018 granted from it |
| Jun 21, 2018 | 2018/0169191 | ADRENOCORTICOTROPIC HORMONE-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR FABRICATING AND USING THEREOF | Pharmaceuticals | Eton Pharmaceuticals, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.